Forskning ved Københavns Universitet - Københavns Universitet

Forside

Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas: Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Jens Pedersen-Bjergaard
  • Jens Ersbøll
  • Hilda Mygind Sørensen
  • Keiding, Niels
  • Severin Olesen Larsen
  • Preben Philip
  • Mogens Salling Larsen
  • Henrik Schultz
  • Nis I. Nissen

Of 602 patients treated for non-Hodgkin's lymphomas, 9 developed overt acute nonlymphocytic leukemia or preleukemia with refractory cytopenia and cytogenetic abnormalities of the bone marrow. A Kaplan-Meier estimate of the cumulative probability of leukemia complications was 6.3 ± 2.6% (mean ± SE) 7 years after start of treatment. All 9 patients with leukemic complications belong to a major subgroup of 498 patients treated with alkylating agents, predominantly cyclophosphamide. The risk of leukemic complications in this subgroup was compared with the risk in 312 patients treated with other alkylating agents for Hodgkin's disease and with the risk in 553 patients treated with dihydroxybusulfan for ovarian carcinoma. Cumulative 9-year risks were 8.0 ± 3.3%, 12.8 ± 3.5%, and 7.1 ± 1.9%, respectively. The general risk of secondary leukemia after long-term treatment with alkylating agents ranges from 1% to 1.5% per year from 2 to at least 9 years after start of treatment.

OriginalsprogEngelsk
TidsskriftAnnals of Internal Medicine
Vol/bind103
Udgave nummer2
Sider (fra-til)195-200
Antal sider6
ISSN0003-4819
DOI
StatusUdgivet - 1 aug. 1985

ID: 202380478